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2 Hypertrophic cardiomyopathy (HCM) is common, inherited and characterised by unexplained 
3 thickening of the myocardium. The British Society of Echocardiography (BSE) has recently published a 
4 minimum dataset for transthoracic echocardiography detailing the core views needed for a standard 
5 echocardiogram. For patients with confirmed or suspected HCM, additional views and measurements 
6 are necessary. This guideline, therefore, supplements the minimum dataset and describes a tailored, 
7 stepwise approach to the echocardiographic examination, and echocardiography’s position in the 
8 diagnostic pathway, before advising on the imaging of disease complications and invasive treatments. 
9
Page 2 of 43Accepted Manuscript published as ERP-20-0042.R1. Accepted for publication: 25-Feb-2021
Copyright © 2019 the authors Downloaded from Bioscientifica.com at 03/16/2021 11:24:15AM
via free access
3
1 Intent behind update
2 These guidelines on hypertrophic cardiomyopathy (HCM) represent a five-year update. They contain 
3 a description of pertinent disease features and the critical echo parameters needed to evaluate the 
4 condition, alongside a recommended protocol. A specific HCM minimum data set, for use as an aide 
5 memoir when reporting, is provided. 
6 The guideline also proposes an echocardiographic approach to diagnosis as well as information on the 
7 use of echo measurements for sudden death risk stratification. This guideline aims to enhance 
8 baseline knowledge and to allow echocardiographers to develop a systematic approach to the image 
9 acquisition and echocardiographic reporting of patients with proven or suspected HCM. The guideline-
10 writing committee anticipates that readers armed with this knowledge will approach these 
11 examinations with confidence, extract as much information about each patient’s condition as possible 
12 and produce unambiguous, standardised reports. These actions will enhance clinical care by limiting 
13 the number of patients who are either under or over-diagnosed and highlight the sub-cohorts of 
14 patients who need additional investigations and treatments. The guidelines end with short sections 
15 covering the use of echo guidance for transseptal alcohol ablation and surgical myectomy as well as 
16 strain, stress and three-dimensional echocardiography in patients with HCM. 
17 Hypertrophic Cardiomyopathy
18 HCM in adults is defined ‘by a wall thickness ≥15 mm in one or more left ventricular (LV) myocardial 
19 segments that is not explained solely by loading conditions’(1), for example, hypertension. In a smaller 
20 number of cases, described in the next section, HCM may be associated with an abnormal wall 
21 thickness which measures less than 15mm. This dimension-based diagnosis covers a diverse group of 
22 diseases, both inherited and acquired, which differ in their pathophysiology and management. 
23 Due to the challenges in certain aspects of diagnosis and management of this patient group, referral 
24 to specialist centres focused on inherited cardiac conditions and cardiomyopathies is recommended 
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1 for patients with suspected or confirmed disease(1). Where possible, echocardiographers should 
2 obtain dedicated training in the scanning and interpretation of this patient group. 
3 The condition affects between 0.2%(2) and 1.4% of individuals(3). Disease complications are 
4 reasonably common; in a multi-centre longitudinal study of patients with HCM, atrial fibrillation 
5 occurred in 20%, sudden cardiac death or resuscitated cardiac arrest in 4%(4) and left ventricular 
6 systolic dysfunction (ejection fraction <50%) in 8%(5).  
7 The pattern of inheritance is autosomal dominant. A clinically meaningful gene change (found 
8 predominantly in MYBPC3 and MYH7) occurs in a fifth of patients where the family history is negative, 
9 and a half where it is positive(6). Finding a disease-causing gene change allows testing of family 
10 members using pre-symptomatic screening. 
11 Echocardiography’s Position in the Diagnostic Pathway – Wall thickness
12 Accurate measurement of wall thickness is fundamental to decision-making. Because of this, the 
13 echocardiographic examination is a key component of the diagnosis pathway.  Ancillary features such 
14 as left ventricular outflow tract obstruction (LVOTO) do not contribute. 
15 Measurements should be made in short-axis views orthogonal to the circumference of the 
16 endocardium and epicardium, wherever maximal wall thickness occurs. Elements attached to but not 
17 incorporated in the septum should be excluded (Figure 1), as this will overestimate wall thickness and 
18 run the risk of misdiagnosis of HCM.  The report should state if the study failed to visualise any part of 
19 the LV (often the basal anterior and anterolateral walls) and recommend alternative imaging 
20 modalities, specifically cardiovascular magnetic resonance.  
21 The dimensional threshold for HCM depends on the location of hypertrophy as well as the clinical 
22 context. In apical HCM, where normal tapering of both cavity and epicardium is lost, the apical wall 
23 thickness may be less than 15 mm(7).  One criterion defines apical HCM when the ratio between apical 
24 and basal wall thickness exceeds 1.3: 1(8). Visualisation of this area can be difficult and may require 
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1 the use of myocardial contrast (Figure 2). By ensuring the apical four, two and three-chamber view 
2 section the apex, the echocardiographer will avoid giving the impression of apical hypertrophy by 
3 foreshortening views. Apical wall thickness should be measured in the short-axis view, ensuring the 
4 cut is not oblique to the long axes of the LV. 
5 In first-degree relatives - who have a 50% risk of inheriting the causative gene - the wall thickness 
6 threshold for diagnosis of HCM is 13 mm (1).  The yield of positive screening examinations in first 
7 degree relatives vary based on the population tested; in one report, 5% of first-degree relative children 
8 were diagnosed with HCM(9), rising to 30 % of a mainly adult cohort in another, where many had a 
9 disease-causing gene(10). A feature of HCM is age-related penetrance, where the percentage of 
10 individuals carrying the disease-causing gene who express the condition increases with age. The yield 
11 of clinical screening is higher in families where the disease onset has been in childhood(9,10).
12 HCM featuring the so-called dilated-hypokinetic or ‘burnt-out’ phase (5), or due to specific gene 
13 mutations(11–13), can be associated with only mild increases in wall thickness. 
14 Grey Cases
15 Ethnicity, hypertension, renal disease, significant aortic stenosis, increased body mass index and 
16 athletic remodelling all influence left ventricular hypertrophy. Increased LV wall thickness secondary 
17 to these processes may fall into a ‘grey zone’, overlapping with the degree of LV hypertrophy (LVH) 
18 seen in HCM (Figure 3). For example, a wall thickness of 15 -20 mm can occur in hypertensive heart 
19 disease in individuals of African/Afro-Caribbean ethnicity, whereas the same degree of hypertrophy 
20 in a Caucasian hypertensive patient would suggest HCM(1). LVH in hypertensive heart disease and 
21 athletic remodelling tends to be uniform and symmetrical. 
22 In athletes, gender, in addition to ethnicity, is relevant. Wall thickness is lower in female athletes than 
23 their male counterparts and does not exceed 13 mm in Caucasian athletes or 15 mm in athletes of 
24 African/Afro-Caribbean ethnicity(14). In a study of athletes with HCM compared with athletes without 
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1 HCM(15), the diagnosis was definite in most individuals as maximal wall thickness was >16 mm, and 
2 often the LVH was distributed non-uniformly. The scenario in which there was uncertainty – where 
3 LVH was 13-16 mm and concentric (defined by a relative wall thickness of >0.42 (see BSE guidelines 
4 on normal reference intervals for cardiac dimensions and function for more information (16)) – 
5 cropped up in only 14% of athletes with HCM. Measures like left ventricular cavity size (previously 
6 reported to be a useful differentiator between HCM and athletic heart; being larger in the latter (17)) 
7 showed modest performance in picking out athletes with HCM. Additional tests were required to 
8 distinguish these individuals from athletes with physiological remodelling.
9 Recommended Language in Echocardiography Report
10 Echocardiography’s pivotal role means that a study’s interpretation can strongly influence the clinical 
11 team’s diagnostic decision. Because of this, we encourage the use of standardised language when 
12 reporting.  In instances where there is uncertainty, ‘raises the possibility of HCM’ is recommended. In 
13 individuals undergoing screening, where there is no evidence of left ventricular hypertrophy, the 
14 conclusion should contain the following suggested phrase: ‘wall thickness is normal’.  The proposed 
15 language provides an objective statement about the echocardiogram findings, rather than a definitive 
16 clinical assertion. Hence ‘wall thickness is normal’ is not the same as ‘does not have HCM’. 
17 Echocardiographers should exercise their judgement, but when the echocardiographic images show 
18 unequivocal evidence of HCM in an appropriate clinical context (clear-cut apical HCM, gross 
19 hypertrophy in a young patient and definite LVH in a screening echocardiogram), the phrase 
20 ‘consistent with HCM’ should be used.
21 Post-echocardiography Work-Up
22 In patients with suspected HCM, the clinical team will contextualise the echocardiography report with 
23 information regarding past medical and family history, blood tests and ECG results, and often 
24 cardiovascular magnetic resonance.  In grey cases, clinicians judge whether the degree of hypertrophy 
25 matches the severity of the comorbidity (Figure 3). Clarification of the diagnosis in these instances is 
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1 possible after assessing the response of wall thickness and LV mass to a sustained period of reduced 
2 afterload, for example, improved blood pressure control in the hypertensive patient, weight loss in 
3 the obese individual, aortic valve replacement in the patient with severe aortic stenosis or cessation 
4 of training in the athlete(18). In exceptional cases where there is non-apical hypertrophy measuring 
5 less than 15 mm, and an ECG highly suggestive of underlying cardiomyopathy, the clinical team might 
6 screen first-degree family members to look for clear-cut evidence of HCM. Given the likelihood of 
7 finding a negative result on gene testing of confirmed cases, it is rarely used as a diagnostic tool when 
8 there is ambiguity about the diagnosis. 
9 Phenocopies
10 It is possible to find within the population of patients with hypertrophic cardiomyopathy rarer 
11 conditions, called phenocopies or ‘mimics’(19). In general, these will come to light during clinical 
12 evaluation of the patient’s medical history, family history, physical examination and the results of 
13 blood tests, including genetics, and other imaging modalities. However, there are particular features, 
14 termed ‘red flags’, which should alert the echocardiographer to the possibility of a phenocopy (Table 
15 1). Of these, cardiac amyloidosis is the most obvious due to its classical signs: increased biventricular 
16 wall thickness, poor long axis function, relative sparing of apical longitudinal contraction and global 
17 longitudinal strain (although not pathognomonic of amyloid), interatrial and valvar thickening, 
18 pericardial effusion, and mismatch between the degree of LVH seen on echo and low amplitude 
19 voltages on ECG.  Diagnosing HCM should be avoided immediately after an acute cardiac injury such 
20 as myocarditis as the myocardium becomes oedematous and thickened; these changes resolve with 
21 time. 
22 Defining the pattern of hypertrophy in HCM
23 The echocardiographic report should detail the distribution of LVH using the schema described in 
24 Figure 4 as this informs the clinical team of the likelihood of finding a disease-causing gene change; 
25 being highest in patients with a reverse curvature pattern and lowest in those with a sigmoid septal 
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1 pattern(20).  Right ventricular hypertrophy is present in around 20% of patients with HCM. The 
2 echocardiographer should report this as it occurs in disease mimics; however, it does not add to the 
3 likelihood of finding a disease-causing mutation. 
4 Hypertrophy can also extend to the papillary muscles, which can contribute to mid-cavity obstruction. 
5 Additional morphological abnormalities of papillary muscles in HCM which can cause LVOT obstruction 
6 include antero-apical displacement, double bifid(21) and anomalous papillary muscles which insert 
7 directly into the mitral valve leaflets(22,23). Bands running between the apex and basal anteroseptal 
8 wall are seen in HCM(24).
9 Echo assessment in risk stratification and disease complications
10 Risk stratification of sudden death is the process clinicians follow to decide which patients should 
11 receive an implantable cardioverter-defibrillator. Using the European Society of Cardiology (ESC) 
12 calculator(1), it is possible to generate an estimate of the five-year risk of sudden death and categorise 
13 patients into low, intermediate, and high-risk groups. Echocardiography provides three of the seven 
14 parameters required in the online tool (maximal wall thickness, LVOT gradient and 2D parasternal long 
15 axis left atrial size). To allow this critical information to be accessed rapidly by the referring clinician, 
16 the conclusion for every report in a patient with suspected or confirmed HCM should contain these 
17 parameters. Although not in the ESC risk calculator, the presence of left ventricular impairment(5) and 
18 an apical aneurysm(25) is also essential to include in the study conclusion as they modify risk of sudden 
19 cardiac death.  
20 The importance of reporting cardiac rhythm in every echocardiogram report is particularly relevant in 
21 HCM as a significant proportion of patients will develop atrial fibrillation. The finding of new atrial 
22 fibrillation should be directly communicated to the referring team as anticoagulation is essential to 
23 prevent stroke or other embolic complications.  
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1 Heart failure can occur due to systolic impairment, diastolic dysfunction and LVOT obstruction. As a 
2 measure of systolic function, ejection fraction (EF) can be misleading in HCM being normal even when 
3 markers of systolic dysfunction such as abnormal regional wall motion and global longitudinal 
4 strain(26) (see the section below) are present. Nonetheless, the absolute value helps clinical teams to 
5 identify patients in whom systolic dysfunction is likely to develop (50-60%) and those in whom it is 
6 overt (<50%)(5). Accurately determining EF using Simpson’s biplane, and three-dimensional 
7 quantification where possible, and highlighting instances when this measurement is discordant with 
8 the systolic function will aid clinical management. Longitudinal systolic function should be assessed 
9 using tissue doppler imaging and in select cases strain (see section below), while radial systolic 
10 function should be assessed visually. Outcomes are generally adverse once the EF falls below 50% (5). 
11 Below this level, clinical teams should consider medications(1), heart transplant(1) and device therapy 
12 (27).
13 Diastolic dysfunction is common in HCM and results in elevated filling pressures and dilatation of the 
14 left atrium, whose diameter in the parasternal long axis is a predictor of sudden death in the ESC risk 
15 calculator (28), and of stroke and other thromboembolic events (29). Accurate classification of 
16 diastolic function grade is challenging in HCM due to the concomitant presence of left ventricular 
17 outflow tract obstruction and mitral regurgitation in many patients. Many independent echo variables 
18 have weak correlations with filling pressures. As such integration of several parameters is necessary 
19 to quantify diastolic function accurately. Diastolic function assessment should include Doppler tissue 
20 imaging and pulmonary vein Ar timings as per BSE guidelines(30). 
21 It is essential to identify patients with preserved left ventricular ejection fraction but a restrictive 
22 diastolic filling pattern, which is often accompanied by pulmonary hypertension(31). These patients 
23 have adverse outcomes(32) and should be observed closely for evidence of deterioration as heart 
24 transplant is an option when symptoms related to heart failure are resistant to medical treatment(31). 
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1 Left ventricular outflow tract obstruction occurs as a result of a reduced cross-sectional area of the 
2 outflow tract due to hypertrophy, abnormalities of the mitral valve apparatus, and in most patients 
3 supranormal ejection, which drags the anterior mitral valve leaflet anteriorly towards the basal 
4 septum. The mitral valve coaptation is disrupted, with the resultant jet of mitral regurgitation in the 
5 majority of patients being directed posteriorly in mid-to-late systole (65% based on a recent study of 
6 patients undergoing myectomy with systolic anterior motion-related mitral regurgitation(33)). The 
7 same study found that posteriorly directed mitral regurgitation occurred in approximately a third of 
8 patients with intrinsic mitral valve disease.
9 There is a spectrum of LVOTO defined according to the severity and whether it is present at rest or 
10 with provocation (Table 2). Echocardiographers should try to provoke LVOT obstruction in every 
11 patient at the bedside by re-imaging while the patient is performing a Valsalva manoeuvre and in a 
12 seated and standing position. Obstruction in the mid and apical LV and right ventricle can also occur 
13 due to narrowing of the cavity as neighbouring myocardial walls contract towards each other. 
14 Accurate identification of the site of obstruction is relevant to guiding treatment strategies. 
15 In patients who fail to respond to medical therapy directed at relief of LVOT obstruction, invasive 
16 septal reduction therapies (surgical myectomy and alcohol septal ablation) are considered. Given the 
17 potential complications of invasive therapies, it is important that patients fulfil the necessary clinical, 
18 anatomical, and hemodynamic criteria to determine suitability for a procedure, and this decision is 
19 based heavily on the echocardiographic assessment. 
20 Although a complete discussion of the work-up for these procedures is outside this guideline’s remit, 
21 pertinent echocardiographic features are summarised in Table 3. A clear description of the nature of 
22 LVH, mitral valve abnormalities, additional areas of obstruction, and aortic valve disease supports 
23 decision-making.  The focus is on identifying those elements  that point to the need for surgical 
24 intervention and not alcohol septal ablation. Surgery can address features aligned with the latter , but 
25 the converse is not true for alcohol septal ablation. 
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1 Alcohol septal ablation is performed through an angiographic percutaneous approach and provides a 
2 suitable alternative for patients of advanced age or with significant comorbidities that would lead to 
3 an increased surgical risk. Injection of alcohol via a septal perforator branch of the LAD is performed 
4 into the target myocardium. This site is the hypertrophied basal septum adjacent to the point of 
5 anterior mitral valve leaflet-basal septal (systolic anterior motion-septal) contact, creating an acute 
6 infarction and progressive thinning of the myocardium with scar formation over a 6-12-month period.  
7 Selective intracoronary injection of contrast is essential to guide the selection of the appropriate 
8 septal perforator vessel, ensuring that the selected branch supplies only the targeted area of the 
9 myocardium, with no enhancement of remote areas such as the papillary muscles, inferior wall of the 
10 LV, or right ventricular free wall. A decrease in resting and provocable LVOT gradients is seen 
11 immediately because of myocardial stunning, with a progressive reduction in resting and dynamic 
12 LVOT gradients over 3-6 months.
13 Finally, the examination should include careful evaluation for aneurysm formation and associated 
14 thrombi in patients with apical HCM using contrast when necessary (Figure 2). Table 4 describes the 
15 relevance of various parameters captured by the echocardiography examination and Table 5 the 
16 minimum data set. A protocol for the transthoracic echo study in HCM is described in Table 6. 
17 Stress Imaging in HCM
18 By imaging the heart during controlled exercise, stress echocardiography can unmask latent 
19 obstruction in symptomatic patients whose baseline transthoracic echocardiography – despite the 
20 previously described physiological manoeuvres – has not shown LVOT gradients ≥ 50 mmHg. 
21 Symptom-limited exercise is safe using an exercise bike or treadmill. There is some evidence to suggest 
22 that treadmill exercise can provoke higher LVOT gradients compared to semi-supine bicycle 
23 exercise(34). Dobutamine is not employed in HCM since this infusion can induce LVOTO in normal 
24 subjects. When the patient has reached peak exercise, images are obtained within 60-90 seconds to 
25 detect obstruction which can be present before or after the patient’s heart rate reaches 85% of target 
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1 heart rate. The protocol in Table 7 suggests an optimal scanning order to utilise peak heart rate with 
2 minimal changes to the acoustic window. Table 8 illustrates the data acquired in each step of the 
3 protocol.  In specific scenarios, the echocardiographer can employ additional measures to provoke 
4 LVOT obstruction. For patients with postprandial symptoms, exercise after eating is useful(35) while 
5 for those who cannot exercise, administering GTN spray can unmask obstruction(36). 
6
7 Strain Imaging in HCM
8 Measurement of global longitudinal strain (GLS) by two-dimensional speckle tracking 
9 echocardiography is becoming more widely used in current practice. Strain is a measure of myocardial 
10 deformation in multiple directions throughout the cardiac cycle. Most commonly, analysis based on 
11 the Lagrangian method (derived from speckle tracking techniques) expresses strain as a fractional 
12 change in length. Shortening of the myocardium becomes a negative value and lengthening of the 
13 myocardium a positive value(37). In HCM, reduced overall left ventricular GLS occurred in individuals 
14 with preserved ejection fraction(38).  A recent systematic review has shown an association between 
15 abnormal GLS and adverse outcomes(39).  
16 However, the author group feel that several practical considerations limit routine use in every HCM 
17 patient. These include the expertise and experience needed to ensure the strain curves generated are 
18 accurate and the potential difficulties in tracking where there is gross hypertrophy, apical hypertrophy 
19 or apical insertion of the papillary muscles. Consequently, inter-observer variability may well be higher 
20 in HCM than for dilated cardiomyopathies. Finally, strain-based measures are yet to be adopted into 
21 clinical HCM guidelines and so will not routinely alter patient management. 
22 For this reason, we recommend that GLS is used to help distinguish HCM from cardiac amyloidosis, 
23 and athletic remodelling. This position will be re-evaluated in the next update of the guideline as more 
24 evidence emerges and the technology evolves.
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2 Besides enabling accurate quantification of left and right ventricular volumes and ejection fraction, 
3 three-dimensional echocardiography also allows echocardiographers to describe mitral valve and 
4 LVOT morphology. Three-dimensional technology is also valuable in transoesophageal 
5 echocardiography to detail SAM’s features and underlying causes (40,41).  We recommend that 
6 patients undergo transoesophageal echocardiography when the transthoracic study suggests 
7 significant abnormalities of the mitral valve apparatus, and to evaluate both the mitral valve and the 
8 LVOT when planning for invasive septal reduction. 
9 Recommendations
10 The echocardiogram report conclusion should include:
11 1. The following suggested phrases: when there is uncertainty: raises the possibility of HCM; 
12 when there is unequivocal evidence of HCM: consistent with HCM; for screening scans with 
13 no LVH: wall thickness is normal. 
14 2. The presence of red flags pointing to a phenocopy.
15 3. The pattern of LVH: sigmoid septal, reverse curvature, apical or neutral.  
16 4. The values for maximal wall thickness, LVOT gradient and LA size. 
17 5. The presence or absence of disease complications. 
18 a. Left ventricular cavity size
19 b. Systolic dysfunction with EF 50-60%, EF<50%. 
20 c. Diastolic dysfunction, specifically the presence of a restrictive filling pattern with 
21 preserved ejection fraction.
22 d. Systolic anterior motion, mitral regurgitation, LVOT obstruction and other forms of 
23 obstruction; at rest and with provocation. Evidence of intrinsic mitral valve disease.
24 e. Aneurysm formation.
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1 6. Image quality, completeness of LV visualisation and need for contrast and transoesophageal 
2 echocardiography, and cardiovascular magnetic resonance.  
3 Conclusion
4 Transthoracic echocardiography plays an essential role in the assessment of patients with proven or 
5 suspected HCM, and their first-degree family members. The guideline writing committee hopes that 
6 this document equips readers with the knowledge and tools needed to perform and report these 
7 studies to a uniformly high level. 
8
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9 Figure 1. Measurement of Wall Thickness by Echocardiography
10 Figure 2. Use of Contrast in Apical Hypertrophic Cardiomyopathy 
11 Figure 3.  Thinking Underlying Clinical Decision-Making in HCM
12 Figure 4. Different Phenotypes of Left Ventricular Hypertrophy in Hypertrophic Cardiomyopathy
13 Figure Legends
14 Figure 1. The challenges to accurate wall thickness measurement vary at each left ventricular chamber 
15 level. Dashed lines represent erroneous measurements and solid lines accurate measurements.  
16 Figure 2.  An apical four-chamber acquisition enhanced with contrast to show apical hypertrophic 
17 cardiomyopathy complicated by aneurysm formation. 
18 Figure 3.  This schematic demonstrates various scenarios and the corresponding likelihood of the 
19 condition. Once investigations are complete, and a full clinical picture is available, this information is 
20 weighed by clinicians to reach a final diagnosis. Between cases where the likelihood of the condition 
21 is the same as the background population (left-hand side, green shading) and definite disease (right-
22 hand side, green shading), lies the diagnostic grey zone (grey shading). 
23 Figure 4. Echocardiographic images are displayed for the four main patterns of hypertrophy, 
24 accompanied by the criteria for each pattern. 
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2 Table 1. Echocardiographic Clues to the Presence of Phenocopies
Condition Echocardiographic ‘Red Flags’ which raise the possibility of a phenocopy *
Cardiac amyloidosis Thickened intreratrial septum, mitral and tricuspid valves and right ventricular 
free wall, mild to moderate pericardial effusion. Ground-glass appearance of 
the myocardium. Global hypokinesia (with and without LV dilatation) in TTR 
amyloidosis. Markedly reduced longitudinal function, relative sparing of 
apical longitudinal contraction/global longitudinal strain, a mismatch 
between LVH on echo and low amplitude voltages on ECG. 
Fabry disease Thickened mitral and tricuspid valves and right ventricular free wall, 
concentric LVH, Global hypokinesia (with and without LV dilatation).   
Myocarditis Thickened right ventricular free wall, mild to moderate pericardial effusion, 
global hypokinesia (with and without LV dilatation)
Danon disease Extreme concentric LVH, global hypokinesia (with and without LV dilatation)
Pompe disease Extreme concentric LVH








 Right ventricular outflow tract obstruction
3 *Adapted from Rapezzi et al(19) and Elliott et al(1). 
4
5
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1 Table 2. Definition of LVOT obstruction. 
LVOT gradient at rest and with physiological provocation Definition
Gradient ≥30mHg at rest Basal or resting 
obstruction
Gradient ≤30mmHg at rest and ≤30mmHg after provocation Non-obstructive
Gradient ≤30mmHg at rest but >30mmHg with physiological provocation Labile, provocable or 
dynamic obstruction
2 Adapted from Gersh et al. (42)
3 Table 3. Use of Echocardiography When Determining Optimal Invasive Septal Reduction Approach
Favours surgical myectomy Aligned with alcohol ablation 
strategy
Unfavourable for either
Septal thickness > 25mm Focal basal septal hypertrophy 
or sigmoid septal morphology
Apical hypertrophy
Central or anteriorly-directed mitral 
regurgitation due to intrinsic valve 
disease
Posteriorly-directed mitral 
regurgitation secondary to 
systolic anterior motion
Abnormal mitral subvalvar apparatus 
contributing to obstruction
Mid-cavity obstruction 
Concomitant aortic valve disease or 
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2 Table 4. Rationale for Key Echo Parameters in Hypertrophic Cardiomyopathy
Feature Prognostic Relevance Role in ESC HCM Guidelines(1)
Left atrial diameter
 
Sudden cardiac death (28), with >48 mm 
predicting all-cause mortality(43). Risk of 
thromboembolism increases 
exponentially (29)
In risk calculator. If LA >45mm, 
for six to twelve monthly 
ambulatory monitoring
Indexed Left atrial 
volume
>34 mL/m2 predicts all-cause mortality, 
heart transplantation, sudden cardiac 
death, and appropriate implantable 
cardioverter-defibrillator therapy (26)
Mitral valve filling 
pattern 
Restrictive filling pattern in HCM 
patients with heart failure with 
preserved ejection fraction carry 
adverse prognosis HCM(32)
Left ventricular wall 
thickness




>30 mmHg predictor of sudden cardiac 
death and heart failure(28,44) 
In risk calculator. If the patient 
has symptoms and > 50 mmHg 
LVOTO resistant to medical 




Ejection fraction <50% associated with 
unfavourable outcome(45)
When ejection fraction <50% in 
patients with NYHA III-IV 
despite optimal medical 
therapy, heart transplant 
indicated
3
4 Table 5. Minimum Dataset
Structure and Function Measurement
Left atrium size Diameter (mm) Indexed biplane volume (mL/m2)
Mitral valve inflow 
Doppler







Diastolic wave (m/s) Ar wave (m/s) Ar duration (ms)
Mitral regurgitation Severity Mechanism Direction of jet
Systolic anterior motion Yes/No Valvular or chordal Contact plaque
Left ventricle wall Septum at basal Anterior wall at Lateral wall at basal Inferior wall at basal 
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1  In individuals being screened for HCM
2
3
thickness in short axis 
view
level, papillary 
muscle level and 
apex level (mm)
basal level, papillary 
muscle level and 
apex level (mm)
level, papillary 
muscle level and 
apex level (mm)
level, papillary muscle 
level and apex level 
(mm)




LV volumes End-diastolic 
Volume (ml), 




(ml), indexed to 




LV systolic function Ejection fraction 
by Simpson’s 
Biplane (%)
Ejection fraction by 
visual assessment 
when Simpson’s 
Biplane cannot be 
calculated (%)
Global longitudinal 
strain in selected 
cases (%)
Tissue Doppler Imaging  Anterolateral 








Inferior annulus* (Sm, 
E’, A’)
(cm/s)
LVOT or intra-cavity 
obstruction (defining 
which)
Resting (mmHg) Valsalva (mmHg) Sitting (mmHg) Standing (mmHg)
Right ventricle (RV) Size and function RV hypertrophy 
(mm)




and inferior vena cava
Severity Probability of 
pulmonary 
hypertension(46)
Inferior vena cava 
size and collapse 
response
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1 Table 6. Transthoracic HCM protocol
2
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Measurement View Modality Explanation Image
LA diameter PLAX 2D 
Unit: mm 
Measure LA dimension at end-systole 
just after the aortic valve closes using 
2D acquisition as per BSE normal 
reference intervals guidelines (16). LA 
diameter is one of the criteria used in 
ESC risk calculator of SCD. Record in 
report conclusion.
SAM PLAX M-mode Place M-mode cursor through the MV 
leaflet tips, ensuring image is on-axis.






Mid-systolic notching and coarse 
systolic fluttering of the aortic valve are 






2D Increased echogeneticity occurs in the 
basal anteroseptal wall due to fibrosis 
where leaflet contact occurs due to 
SAM.
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Freeze 2D image at end-diastole. 
Calliper diameter of maximal wall 
thickness – wherever it occurs -  in the 
anterior, septum, inferior and lateral 
walls at the basal, mid-ventricular and 
apical levels(47). 
Be careful not to include right 
ventricular (RV) wall, papillary muscles, 
trabeculations or moderator band. 
The thickest segment may not be in the 
septum. 
Maximal wall thickness is one of the 
criteria used in ESC risk calculator of 






A4C, A2C 2D Units: mL/m2 and % LV volumes should be obtained using 
2D imaging from A4C and A2C, and 
wherever possible 3D imaging. 
Trace the endocardial border. LV length 
is defined as the distance between the 
midpoint of the mitral valve level line 
and the most distal point of the LV 
apex. Take care to ensure the LV is not 
foreshortened.  Papillary muscles and 
trabeculations are excluded from the 
volumes and considered part of the 
chamber.
Measure at end-diastole (onset of QRS 
complex) and end-systole(the frame 
before MV opens, where AV just 
closes)(16).  Volumes are indexed to 
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A4C,A2C 2D biplane volume using 
independent A4C and A2C 
views.
Units: ml/m²
LA volume should be obtained from 
apical 4- and 2-chamber windows 
(separated by 60° of rotation), 
optimised for LA assessment, using the 
biplane Simpson’s method. Maximal LA 
volume should be obtained from the 
frame immediately prior to mitral valve 
opening. Values should be reported 
after indexing for BSA(16,30). 
Trace the inner aspect of the left atrial 
wall. At the mitral valve level, the 
contour is closed by a straight line 
between along the plane of the mitral 
valve annulus. Exclude left atrial 
appendage and pulmonary veins. 
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in all four 
walls
A4C, A2C PW TDI
Units: cm/s
Systolic (Sm), early (E’) and atrial (A’) 
relaxation velocities at anterolateral 
and inferoseptal walls(30). 
In screening studies, there is an 
argument for averaging E/ across 
anterolateral, inferoseptal, inferior and 
anterior LV annulus as a value <13.5 
cm/s can be  useful in identifying 
genotype positive phenotype negative 
individuals(48).
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This is recommended when cardiac 
amyloidosis or athletic remodelling are 
being considered.  Average global 
longitudinal strain (GLS) is calculated 
using the apical long axis (A3C), four 
chamber A4C and two chamber A2C 
standard views. High quality image 
acquisition, maintaining a frame rate of 
40 to 90 frames/second at a stable 
heart rate is key. Clear endocardial and 
epicardial definition (seen throughout 
the cardiac cycle) is required to ensure 
adequate segmental tracking during 
systole and diastole. Markers are placed 
in each of the respective basal and 
apical regions, utilising automated 
tracking where possible to maintain 
reproducible results. ROI should be 
manipulated as required to fit the 
myocardium. Automated tracking 
should also be combined with a visual 
assessment of tracking in each view 
across the whole region of interest 
including the endocardial and epicardial 
border. If more than two segments in 
any one view are not adequately 
tracked, the calculation of GLS should 
be avoided.
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A4C, A5C CW Doppler (or PW with HPRF 
as a significant gradient will 
alias on PW Doppler). 
Sampling PW Doppler 
throughout the LV cavity is a 
useful tool to pinpoint the 
exact location of obstruction if 
unclear on colour. 
Units: mmHg
Assess obstruction gradients at rest, 
with Valsalva manoeuvre and in sitting 
and standing positions. Align CW 
Doppler through entire turbulent colour 
flow for peak obstruction velocity.
Peak LVOT obstruction gradient is one 
of the criteria used in ESC risk calculator 
of SCD. Record in report conclusion.
Multiple LV 
gradients
A4C, A5C CW Doppler
Colour flow mapping
Units: mmHg
Intra-cavity obstruction at the apex 
produces an additional Doppler signal 




A4C, A5C CW Doppler
Colour flow mapping
Units: mmHg
When mitral regurgitation occurs in the 
context of SAM or prolapse, its onset is 
later in mid to late systole.  Otherwise, 
its onset is in early systole helps 
distinguish it from the LVOT signal 
which begins later in systole (see right 
hand image). 
LVOT obstruction is dagger-shaped due 
to the progressive decrease in LVOT 
orifice size as systoles progresses but of 
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lower maximal velocity compared to 
mitral regurgitation. The lower image 
shows superimposed CW envelopes in a 
patient with mitral regurgitation and 
LVOTO.  In this case mitral regurgitation 
starts later in systole, so timing of onset 
is a less useful discriminator. However, 
the velocity for the mitral regurgitation 









Mitral regurgitation quantification may 
be limited as the PISA dome may merge 
with turbulent LVOT flow. Mitral 
regurgitation secondary to SAM is 
mainly posteriorly directed. When 
quantitative assessment of MR is 
precluded by LVOTO, other indicators of 
MR severity should be considered. For 
example, an E velocity of < 1.3 m/s and 
an E/A ratio <1 are strongly suggestive 







2D Describe MV anatomy; elongation of 
both leaflets, presence of SAM (and 
which leaflet(s) it involves), aberrant 
chordae running from anterior mitral 
valve leaflet to LVOT, anomalous 
papillary muscles running directly into 
the mitral valve leaflets and 
displacement of the papillary muscles  
antero- apically. If the anterior mitral 
valve leaflet is elongated (>16 mm), this 
increases the likelihood of LVOT 
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Measure peak systolic (S) velocity, peak 
diastolic (D) velocity, the S/D ratio, peak 
atrial reversal (Ar) velocity in late 
diastole and the duration of the Ar 
velocity.  
In the apical 4-chamber view, superior 
angulation of the transducer and use of 
colour flow will help locate the 
pulmonary veins. This angle often brings 
the aorta into the visualised plane. The 
right upper is usually easiest and is next 
to the atrial septum. If the signal is 
weak, ask the patient to adopt a more 
supine position. Place the PW Doppler 
sample volume (1–3 mm) 1–2 cm into 
the right upper vein. Wall filter settings 
should be lowered (100–200 MHz). Aim 
to include clear visualisation of the 
atrial reversal velocity waveform. 
Measurements should be averaged over 
3 cardiac cycles, at end expiration.
Additional parameters for diastolic 
function should include A wave 
duration on transmitral inflow. For the 
measurement of the mitral valve A 
wave duration, the PW Doppler sample 
should be placed at the level of the 
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annulus rather than at the leaflet tips. 
This provides a cleaner signal for the 
start and end of the wave. See BSE 
guidelines for diastolic function(30).











Units: Vmax m/s, peak 
gradient mmHg









Freeze the PLAX or subcostal view of 
the RV free wall, scroll to end diastole 









Modify both the RV inflow and outflow 
to assess for RV hypertrophy and RV 
outflow tract obstruction.
Use colour box as a guide for highest 
RVOT velocity. 
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2D Basal septum has scalloped appearance 
and is hypokinetic/akinetic. 
Colour flow Doppler should be applied 
to the area of myectomy to assess for 
iatrogenic VSD (systolic flow), and a 
denuded septal perforator vessel 
(diastolic flow). The pre-procedure HCM 
morphology cannot be determined in 
patients who have undergone a septal 



















Apical HCM can be accompanied by an 
apical aneurysm which encourages 
thrombus formation (see non-contrast 
image on right). Have a low threshold 
for giving contrast (far right image) if 










2D Four distinct phenotypes describe the distribution of left ventricular hypertrophy. Comment on 
morphology in the report conclusion.
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A5C/A3C (view which 
obtained the highest 
gradient at rest). 
CW Doppler (or PW with 
HPRF as a significant 
gradient will alias on PW 
Doppler). Sampling PW 
Doppler throughout the 
left ventricular cavity is a 
useful tool to pinpoint the 
exact location of 
obstruction if unclear on 
colour. 
Units: mmHg
Increase in stroke volume with 
exercise. Use colour box as a 
guide to aim CW Doppler beam 
through area of turbulence 
obtaining the highest gradient. 
Assessment of LVOT obstruction 
assessment is performed prior 
to LV assessment it can be a 
short-lived phenomenon
MR A4C, A3C Colour mapping
CW doppler
Be careful to differentiate mitral 
regurgitation from LVOT 
obstruction. 
MV A4C PW Doppler
Units: cm/s
Peak exercise and intermediate 
stage (100-120bpm).
Pulse at MV leaflet tips to 
obtain inflow Doppler. 
Description of MV morphology 
and SAM at intermediate and 
peak. 
TR A4C (alternative views 
are RV inflow or PSAX, 
however time 









A4C, A2C, A3C, SAX 2D imaging




A4C and A2C for LV volumes 
and Simpson’s Biplane EF. Small 
LV cavity may make measuring 
volumes difficult at 
intermediate and peak stress. 
LV diastolic 
function
A4C, A2C Diastolic TDI parameters in 
anterolateral and 
inferoseptal walls
MV inflow flow Doppler
E/e’ average
Units: cm/s
Peak exercise and intermediate 
stage (100-120bpm).
E/A fusion will occur at high 
heart rates. 
Intermediate imaging with 
supine bicycle only. 
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HCM stress echo protocol – Quick guide





 Resting BSE HCM guidelines 
2020.








 Perform a resting ECG.







 Obtain resting spirometry tests 
if performing combined CPEX.
 CPEX data is used to establish 








Image 2   
 Bicycle or treadmill method of 
exercise
 Treadmill – resting echo images 
obtained on echo bed.
 Bicycle – resting echo images 
obtained whilst patient on bike 








 Continuous monitoring of ECG 
and BP throughout study.
 Pay particular attention to 
arrhythmias, ST changes and 
potential BP drop at peak 
exercise.





 Treadmill – stopped 
immediately at peak exercise, 
patient is carefully guided back 
onto the echo bed. 
 Bicycle – peak images are 
obtained whilst patient is still 
on bicycle. 
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 Peak exercise images are 
obtained within 60-90s. 
 This is before preload decreases 
and before the patient’s heart 
rate recovers below 85% of THR. 
 See table 1 for echo parameters 
collected at peak exercise.
 Echo measurements are 
calculated post acquisition to 





 CPEX, echo and haemodynamic 
data are combined to produce 
a clinical report. 
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